PD-1/PD-L1-IN-69
PD-1/PD-L1-IN-69 is an orally active PD-L1 dimerization inducer and FAK phosphorylation inhibitor (IC50 = 18.7 nM for human PD-1/PD-L1 interaction). PD-1/PD-L1-IN-69 blocks the PD-1/PD-L1 interaction by stabilizing dimerization within the PD-L1 dimerization pocket, and inhibits VEGF-A-induced FAK phosphorylation and angiogenesis, thereby enhancing immune-mediated tumor cell death. PD-1/PD-L1-IN-69 can be used for research on colon adenocarcinoma.
For research use only. We do not sell to patients.
- Formula: C26H24INO3
- Molecular Weight:525.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PD-1/PD-L1 18.7 nM (IC50) |
In Vitro
PD-1/PD-L1-IN-69 (compound QA9) (0.625-10 μM; 48 h) effectively reverses PD-1/PD-L1-mediated T cell inhibition and exhibits more potent tumor-selective activity in HCT116/Jurkat and MC38/Jurkat co-culture models[1].
PD-1/PD-L1-IN-69 (1 μM; 1 h) is the most potent inhibitor of PD-1/PD-L1 interaction in the HTRF assay, with an IC50 of 18.7 nM[1].
PD-1/PD-L1-IN-69 (6 μM; 24 h) decreases total FAK expression in VEGF-A-stimulated HUVEC cells[1].
PD-1/PD-L1-IN-69 (6 μM; 24 h treatment, 6 h incubation on Matrigel) inhibits VEGF-A-induced tube formation in HUVECs[1].
PD-1/PD-L1-IN-69 (3-6 μM; 24 h) inhibits VEGF-A-induced HUVEC migration[1].
PD‑1/PD‑L1‑IN‑69 (6 μM; 24 h) produces anti‑angiogenic and anti‑migratory effects in HUVECs associated with reduced FAK phosphorylation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116 and MC38 cells
-
Concentration:0.625, 1.25, 2.5, 5, 10 μM
-
Incubation Time:48 h
-
Result:Showed minimal cytotoxicity against HCT116 monocultures at 10 μM with 93% viability.
Induced superior tumor cell death in the coculture system with 70% viability.
Demonstrated dose-dependent cytotoxicity against MC38 cells with 86% and 72% viability at 2.5 and 5 μM respectively.
Enhanced MC38 cell death by 20% in coculture versus monoculture at 5 μM.
-
Cell Line:HUVECs
-
Concentration:6 μM
-
Incubation Time:24 h (treatment); 6 h (incubation on Matrigel)
-
Result:Markedly suppressed VEGF-A-induced tube formation.
-
Cell Line:HUVECs
-
Concentration:3, 6 μM
-
Incubation Time:24 h
-
Result:Significantly attenuated VEGF-A-induced migration at 6 μM.
-
Cell Line:HUVECs
-
Concentration:6 μM
-
Incubation Time:24 h
-
Result:Notably reduced phosphorylation of FAK without affecting total FAK levels.
-
Cell Line:HUVEC cells
-
Concentration:6 μM
-
Incubation Time:24 h
-
Result:Reduced total FAK expression in VEGF-A-stimulated HUVEC cells.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (male, 6−8 weeks old, 18−22 g)[1]
-
Dosage:30; 60 mg/kg
-
Administration:i.g.; daily; 14 days
-
Result:Sustained intragastric administration of QA9 was well tolerated, with no significant alterations in body weight or observable adverse effects.
QA9 exhibited pronounced dose-dependent antitumor activity.
At the higher dose (60 mg/kg), QA9 administration resulted in substantial reductions in tumor volume (75%) and tumor weight (79%), demonstrating superior efficacy compared to NP19 (65 and 70%, respectively) at an equivalent dosage.
The lower dose (30 mg/kg) also elicited significant antitumor effects, with reductions of 57% in tumor volume and 66% in tumor weight relative to vehicle-treated controls.
Histopathological assessment via H&E staining revealed intact cellular architecture and absence of necrosis across multiple organ systems in both treatment groups.
Flow cytometric analysis of tumor-infiltrating lymphocytes showed that QA9 treatment elevated activated helper T cells (CD3+ CD4+: 2.5%) and cytotoxic T cells (CD3+ CD8+: 7.8%) compared to the vehicle control (1.2 and 3.5%, respectively).
Chemical Information
-
Molecular Weight 525.38
-
Formula C26H24INO3
-
SMILES
CC1=C(C2=CC3=C(C=[N+](CCO)C=C3)C=C2)C=CC=C1C4=CC5=C(C=C4)OCCO5.[I-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- PD-1/PD-L1-IN-69
- PD-1/PD-L1
- FAK
- VEGFR
- VEGF-A-induced FAK phosphorylation
- endothelial cell migration
- HUVECs
- tumor-infiltrating T-cell activation
- PD-1/PD-L1 protein-protein interaction
- angiogenesis
- colon adenocarcinoma
- FAK phosphorylation inhibitor
- PD-L1 dimerization inducer
- endothelial tube formation
- Inhibitor
- inhibitor
- inhibit